Search for Stocks /

Bhagiradha Chemicals Q3 FY26: ₹114 Cr Sales, 214 P/E, ₹800+ Cr Capex — Agrochemical Gambler or Long-Term Molecule Machine?


1. At a Glance – The ₹2,833 Cr Puzzle with ₹13 Cr Profit

Bhagiradha Chemicals & Industries Ltd is currently trading at ₹217 with a market cap of ₹2,833 crore. Sounds respectable, right? Now hold your calculator.

TTM sales: ₹500 crore.
TTM profit: ₹13 crore.
Stock P/E: 214.
ROCE: 5.19%.
ROE: 2.53%.
Debt: ₹189 crore.
EV/EBITDA: 64.3.
3-month return: -12%.
1-year return: -24.8%.

Let that sink in.

The company just reported Q3 FY26 sales of ₹113.97 crore with PAT of ₹4.62 crore and EPS of ₹0.36. That’s decent quarter-on-quarter growth. But the valuation? That’s Bollywood hero-level confidence.

Meanwhile, promoter holding sits at 19.6% — and has been drifting down over the years. The company is in the middle of an ₹800+ crore expansion via its subsidiary Bheema Fine Chemicals. Big ambition. Big capex. Big risk.

So the real question:

Is this a future agrochemical powerhouse in the making… or a molecule factory running ahead of its earnings?

Let’s dissect.


2. Introduction – From Lab Scientist to Leveraged Expansion

Bhagiradha Chemicals was founded in 1993 by late Sri S. Koteswara Rao, a former scientist from IICT Hyderabad. This wasn’t some “let’s trade chemicals” story. This started as hardcore chemistry.

Over time, the company built a portfolio of 32 active ingredients across insecticides, fungicides, herbicides, and specialty intermediates. It caters to 100+ domestic and 25+ multinational clients.

But here’s the twist.

For FY25:

  • 97% revenue came from domestic markets.
  • Only 3% from exports.

Despite exporting to USA, Brazil, Germany, UK, Israel, etc., exports form a tiny slice of revenue. Interesting.

Now comes the ambitious part.

Through wholly owned subsidiary Bheema Fine Chemicals Pvt Ltd, the company is executing an ₹800+ crore expansion program in Karnataka. The new plant has:

  • 34 acres
  • 9,002 MT planned capacity
  • Preferential tax rate of 17.16%

Commercial production already commenced in March 2024.

Sounds like a growth story, right?

But whenever capex exceeds annual revenue by 1.6x… auditors start sharpening pencils.

Are we looking at the next specialty chemical winner — or a balance sheet stress

Read Full 16 Point breakdown. Continue reading →
Members get full access to every article.
Become a member
Already a member? Log in
Read Full 16 Point breakdown. Continue reading →